drugset / Trial / NCT00650819

Comparison of Ezetimibe Plus Simvastatin Versus Ezetimibe or Simvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03757)(COMPLETED)

NCT00650819

Phase 3 Completed 240 enrolled Organon and Co Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a multicenter, randomized, double blind; active-controlled parallel groups study enrolling subjects with primary hypercholesterolemia. Subjects receive ezetimibe, simvastatin, or the combination once daily for 8 weeks to determine the effect on LDL-cholesterol.

Timeline

Start
2004-06-01
Primary completion
2005-02-01
Completion
2005-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ezetimibe Unknown 10 mg
Subject Simvastatin Small molecule 20 mg

Indications